/ /

  • linkedin
  • Increase Font
  • Sharebar

    Cardiovascular morbidity and mortality in pregnancy

     

    Prediction of risk

    Several different risk scores have been developed to predict pregnancy risk in mothers with CVD, with the modified World Health Organization (WHO) classification felt to be the most reliable.30 (See “World Health Organization classification of maternal cardiovascular risk factors” at Contemporaryobgyn.net/cv-morbidity.) WHO Pregnancy category I indicates no significant maternal morbidity or mortality. Category II indicates a low risk of maternal mortality and a moderate risk of morbidity.  Category III indicates a high risk of complications with a significantly increased risk of maternal mortality or morbidity and requires careful coordinated care with ongoing monitoring throughout the pregnancy. Some patients are classified as Category II-III with an intermediate risk of maternal mortality and morbidity, depending on their specific anatomy and clinical status. Category IV indicates that pregnancy is contraindicated due to a very high risk of maternal mortality or morbidity, and termination of pregnancy is often recommended. In a validation study comparing risk models for pregnancy complications in CHD, the risk of cardiovascular complications was 0% in WHO Class I, 6.8% in Class II, 24.5% in Class III, and 100% in Class IV.9

     

    Coordination of care

    For patients at increased risk of cardiovascular morbidity or mortality (WHO pregnancy class II or greater), pregnancy care should be coordinated between the maternal-fetal medicine obstetrician and the cardiologist. For patients with CHD, a CHD-trained physician should be involved in the care of the patient and high-risk patients should be managed at a specialized adult CHD center. For patients with the highest mortality risks, pregnancy and delivery should be in a specialized care center as well. The frequency of follow-up depends on the perceived risk to the patient and her clinical status, with follow- up every trimester for low-risk patients (Class II) and every 1 to 2 months or more frequently for patients at highest risk (Class III or IV). In some cases where maternal risk is felt to be excessive, termination of pregnancy should be recommended. A specific plan for labor, delivery, and postpartum care should be created, involving the cardiologist, ob/gyn, and anesthesiologist. For the highest-risk patients, involvement of a cardiac anesthesiologist may be indicated, as well as cardiac interventionalists, pulmonary hypertension specialists, cardiac surgeons and other specialists. Common complications to be anticipated and planned for should include arrhythmias and heart failure. Specific plans for management of complications should include the availability of telemetry monitoring, intensive care unit-level care, availability of transcatheter interventions and cardiac surgery if needed, and the ability to perform cardiopulmonary resuscitation. Prolonged maternal monitoring after delivery is important, as cardiac complications may arise in the postpartum period after successful delivery. Careful planning and integration of care between providers are vital to optimize maternal and neonatal outcomes.

     

    Disclosure The author reports no potential conflicts of interest with regard to this article.

    REFERENCES

    1. Creanga AA, Syverson C, Seed K, Callaghan WM.  Pregnancy-related Mortality in the United States, 2011-2013.  Obstet Gynecol. 2017;130:366-373.

    2. Ouzounian JG, Elkayam U.  Physiologic changes during normal pregnancy and delivery.  Cardiol Clin. 2012:30;317-329.

    3. Knott RJ, Garan H.  Cardiac arrhythmias in pregnancy.  Seminar Perinatol. 2014;38:285-288.

    4. Gorland S, Elkayam U.  Anticoagulation in Pregnancy.  Cardiol Clin. 2012;30:395-405.

    5. Regitz-Zagrosek V, Blomstom LC, Borghi C, Cifkova R, Ferreira R, Foidart JM, et al: ESC Committee for Practice Guidelines. ESC Guidelines on the management of cardiovascular disease during pregnancy: the Task Force on Management of Cardiovascular Diseases during Pregnancy of the European Society of Cardiology (ESC).  Eur Heart J. 2011;32:3147-3197. 

    6. Elkayam U, Gorland S, Pieper PG, Silversides CK.  High-Risk Cardiac Disease in Pregnancy, Parts I and II. J Am Coll Cardiol. 2016;68:396-408 and J Am Coll Cardiol. 2016;68:502-515.

    7. Brickner ME.  Cardiovascular Management in Pregnancy: Congenital Heart Disease.  Cir J. 2014;130:273-282.

    8. Canobbio MM, Warnes CA, Aboulhosn J, Connolly H, Khanna A, Koos BJ, et al.  Management of pregnancy in patients with complex congenital heart disease: A Scientific Statement for Healthcare Professionals from the American Heart Association.  Circ J. 2017;115:e50-e87.

    9. Drenthen W, Boersma E, Balci A, Moons P, Roos-Hesselink JW, Mulder BJ, et al.  ZAHARA Investigators.  Predictors of pregnancy complications in women with congenital heart disease.  European Heart J.  2010;31:2124-2132.

    10. Beauchesne LM, Connolly HM, Ammash NM, Warnes CA.  Coarctation of the aorta: outcome of pregnancy.  J Am Coll Cardiol. 2001;38:1723-1733.

    11. Vriend JWJ, Drenthen W, Pieper PG, Roos-Hesselink JW, Zwinderman AH, van Veldhuisen DJ, Mulder BJM.  Outcome of pregnancy in patients after repair of aortic coarctation.  Eur Heart J. 2005;26:2173-2178.

    12. Veldtman GR, Connolly HM, Grogan M, Ammash NM, Warnes C.  Outcomes of pregnancy in women with tetralogy of Fallot.  J Am Coll Cardiol. 2004;44:174-180.

    13. Gelson E, Gatzoulis M, Steer PJ, Lupton M, Johnson M.  Tetralogy of Fallot:  maternal and neonatal outcomes. BJOG. 2008;15:398-402.

    14. Mertz TD, Jackson GM, Yetman AT.  Pregnancy outcomes in women who have undergone an atrial switch repair for congenital d-tranposition of the great arteries.  Am J Obstet Gynecol. 2011;205:273e1-5. 

    15. Tobler D, Fernandes SM, Wald RM, Landzberg M, Salehian O, Siur SC, et al. Pregnancy outcomes in women with transposition of the great arteries and arterial switch operation.  Am J Cardiol. 2010;106:417-420. 

    16. Presbitero P, Somerville J, Stone S, Aruta E, Spiegelhalter D, Rabajoli F.  Pregnancy in cyanotic congenital heart disease: outcome of mother and fetus.  Circ J. 1994;89:2673-2676.

    17. Drenthen W, Pieper PG, Roos-Hesselink JW, van Lottum WA, Voors AA, Mulder BJM, et a;l. ZAHARA Investigators.  Pregnancy and delivery after Fontan palliation.  Heart. 2006;92:1290-1294.

    18. Walker F.  Pregnancy and the various forms of the Fontan circulation (editorial).  Heart.  2007;93:152-154.

    19. Silwa K, vanHagen IM, Budts W, Swan L, Sinagra G, Caruan M, et al; ROPAC Investigators. Pulmonary hypertension and pregnancy outcomes: data from the Registry of Pregnancy and Cardiac Disease (ROPAC) of the European Society of Cardiology.  Eur J Heart Failure. 2016;19:1119-1128.

    20. Sillesen M, Hjortdal V, Vejlstrup N, et al.  Pregnancy with prosthetic heart valves – 30 years’ nationwide experience in Denmakr.  Eur J Cardiothorac Surg. 2011;40:448-454.

    21. Elkayam U, Goland S.  The search for a safe and effective anticoagulation regimen in pregnant women with mechanical prosthetic heart valves.  JACC. 2012;59:1116-1118. 

    22. Van Hagen IM, Roos-Hesselink JW, Ruys TP, Merz WM, Goland S, Gabriel H , et al; ROPAC Investigators and the EURObservational Research Programme (EORP) Team. Circ J. 2015;132(2):132-142.

    23. Sliwa K, Hilfiker-Kleiner D, Petrie MC, Mebazaa A, Pieske B, Buchmann E, et al.  Current state of knowledge on aetiology, diagnosis, management, and therapy of post-partum cardiomyopathy:  a position statement from the Heart Failure Association of the European Society of Cardiology Working Group on peripartum cardiomyopathy.  Eur J Heart Failure. 2010;12:767-778.

    24. McNamara DM, Elkayam U, Alharethi R, Damp J, Hsich E, Ewald G, et al for the Investigations of Pregnancy-Associated Cardiomyopathy (IPAC) investigators.  Clinical outcomes for periparum cardiomyopathy in North America: Results of the IPAC Study (Investigations of Pregnancy-Associated Cardiomyopathy).  J Am Coll Cardiol. 2015;66:905-914.

    25. Ulkayam U.  Risk of subsequent pregnancy in women with a history of peripartum cardiomyopathy.  J Am Coll Cardiol. 2014;64:1629-1636.

    26. Elkayam U, Jalnapurkar S, Barakkat MN, et al.  Pregnancy-associated acute myocardial infarction: a review of contemporary experience in 150 cases between 2006 and 2011.  Circ J. 2014;129:1695-702.

    27. Roos-Hesselink JW, Ruys TP, Stein JI, Thilen U, Webb GD, Niwa K, et al. Registry of Pregnancy and Cardiac Disease (ROPAC) Investigators.  Outcome of pregnancy in patients with structural or ischaemic heart disease: results of a registry of the European Society of Cardiology.  Eur Heart J. 2012:34:657-665.

    28. Hiratzka LF, Bakris GL, Beckman JA, Bersin RM, Carr VF, Casey DE Jr, et al.  2010 CCF/AHA/AATS/ACR/ASA/SCA/SCAI/SIR/STS/SVM Guidelines for the Diagnosis and Management of Patients with Thoracic Aortic Disease.  J Am Coll Cardiol. 2010;55:327-129.

    29. Pieper PG, Lameijer H, Hoendermis ES.  Pregnancy and pulmonary hypertension.  Best Pract Res Clin Obstet Gynaecol. 2014;28:579-591.

    30. Balci A, Sollie-Szarynska KM, van der Bijl AG, Ruys TP, Mulder BJ, Vliegen HW, et al; ZAHARA-II Investigators. Prospective validation and assessment of cardiovascular and offspring risk models for pregnant women with congenital heart disease.  Heart. 2014;100:1373-1381.

    Beth Brickner, MD
    Dr. Brickner is co-director of the Adult Congenital Heart Disease Program at UT Southwestern Medical Center, Dallas, Texas.

    0 Comments

    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available

    Poll

    Latest Tweets Follow